Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03982446 |
| Other study ID # |
Germline_pancreas |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
March 1, 2016 |
| Est. completion date |
January 3, 2020 |
Study information
| Verified date |
February 2020 |
| Source |
Hellenic Cooperative Oncology Group |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
This study will assess the hereditary component of pancreatic cancer in the largest series of
patients up to date through the parallel analysis of 62 cancer-associated genes. The
investigators will obtain germline DNA from blood samples that have been collected from 2000
to 2019 from patients with pancreatic cancer. The investigators plan to analyze germline DNA
for mutations and single nucleotide polymorphisms (SNPs) in genes that have been previously
linked to a predisposition towards cancer.
The outcome can provide useful insight on the overall understanding of pancreatic
pathogenesis while possible associations with age of diagnosis, tumor stage and other cancer
types might arise. In addition to that, it can lead to the characterization of new variants
or even new genes that predispose to pancreatic cancer.
Confirmed deleterious mutations in established cancer genes can provide valuable clinical
information that can lead to effective, individualized patient management. Furthermore,
family relatives of the individuals found to carry mutations can also benefit from
established screening protocols for various cancer types, such as frequent colonoscopies in
the case of an MMR mutation predisposing for Lynch syndrome, or preventative surgeries in the
case of a deleterious BRCA1 or BRCA2 mutation. In addition to that, specific therapies that
have been previously shown to be effective in breast or ovarian cancer patients with BRCA1 &
BRCA2 mutations, such as platinum-based chemotherapy and PARP inhibitors can be also
effective in mutations carriers with pancreatic cancer.
Description:
Background Pancreatic ductal adenocarcinoma has poor prognosis mainly highlighted by the low
5-year survival rate, which is estimated to be around 6%. Although pancreatic cancer
incidence is approximately 0.5% in the general population, it has a high-mortality rate. It
is being registered as the fourth leading cause of cancer-related deaths in the United
States. Poor prognosis is mainly attributed to the lack of efficient treatment options.
With the majority of pancreatic adenocarcinoma cases being sporadic, familial clustering
(defined by the presence of at least two first degree relatives with pancreatic cancer) is
observed in ~20% of the cases, whereas a clear genetic cause is identified in approximately
half of these cases. Pancreatic cancer is known to occur in a range of cancer predisposing
syndromes, such as hereditary breast and ovarian cancer, Peutz-Jeghers, familial adenomatous
polyposis, Lynch, Li-Fraumeni and familial atypical multiple mole syndromes, while there have
been clear associations with loss-of-function mutations in non-syndromic cancer genes, such
as PALB2 and ATM. In addition, individuals carrying mutations in PRSS1 gene that predisposes
for hereditary pancreatitis are also considered to be at high-risk for pancreatic cancer. It
is therefore clear that pancreatic cancer is not related with a single cancer predisposition
gene, but with numerous known and probably yet to be discovered, cancer susceptibility genes.
On the other hand, the accurate fraction of genetic predisposition in pancreatic cancer
hasn't been determined. Previous studies have evaluated the prevalence of loss-of-function
mutations in known cancer predisposition genes in pancreatic cancer patients through the use
of multi-gene panels. The mutation yield ranged from 3.8% to 9.7% in genes that were
previously found relevant to pancreatic cancer predisposition.
Through these studies, it has been highlighted that family history and stage of pancreatic
cancer or age at diagnosis is not always a predictor of an underlying genetic factor, while
phenotypic heterogeneity is usually associated with mutation status. The search for novel
predisposition genes in pancreatic cancer patients without family history is ongoing through
candidate genes analysis or through whole exome sequencing.
Research methodology Clinicopathological characteristics
Genomic DNA from pancreatic cancer patients will be retrospectively and prospectively
collected from the Hellenic Cooperative Oncology Group (HeCOG) Tumor Repository, through
years 2000-2019. Written informed consent has already been obtained from all patients for the
use and storage of their biologic material along with their approval for their participation
in research studies. The study will be in agreement with the 1975 Helsinki statement, revised
in 1983.
Clinicopathologic characteristics of patients with pancreatic cancer will be retrieved form
their medical record. Diagnosis will be confirmed through pathology reports, which will also
provide information about grade, proliferation rate, histological subtype and lymphovascular
invasion. From the patient medical record, tumor size, nodal involvement as well as
metastatic lesions (TNM staging) will be reported. Importantly, detailed family history will
be collected. The collection of these information will be in compliance with the regulations
of the Bioethics committees of participating hospitals. Clinicopathological characteristics
will be correlated with the different genomic abnormalities identified by sequencing.
Germline DNA extraction
Blood samples will be collected from patients with pancreatic cancer. Germline DNA from white
blood cells will be isolated using a commercially available blood DNA extraction kit.
Germline DNA will then be subjected to mechanical fragmentation via sonication to reach a DNA
size of approximately 200-250 bp for downstream next-generation sequencing (NGS) analysis.
Next-Generation Sequencing
Targeted capture enrichment NGS relies on in-solution hybridization of DNA libraries with
TACS (Targeted Capture Enrichment Sequences) for the identification of germline mutations in
cancer patients. First, TACS that target mutations associated with hereditary cancer (in a
total of 62 cancer predisposing genes) are designed and prepared by PCR followed by
biotinylation. Biotinylated TACS will then be immobilized on streptavidin coated magnetic
beads for subsequent hybridisation with the DNA libraries. DNA libraries are prepared from
patient derived-germline DNA that fulfill quality control criteria (DNA yield, DNA integrity
and fragment size) according to established protocols. Library preparation involves the 3'
end and 5' end adaptor ligation and each DNA library will be barcoded using unique
oligonucleotide DNA sequences to allow subsequent discrimination after sequencing. Subsequent
to barcoding, samples will undergo hybridization using custom made 5'-biotynylated TACS
followed by PCR amplification. Finally, enriched DNA libraries will be normalised and pooled
on a NGS platform prior to paired-end sequencing using manufacturer's protocols.
Bioinformatic and Data Analysis Sequence data from leucocyte (buffy coat) DNA will be
demultiplexed and aligned to the human genome (hg19) using appropriate aligner algorithms
(BWA) to generate a BAM file. A combination of variant calling algorithms will be used to
call germline mutations. Local realignment will be performed for accurate detection of small
insertions and deletions and appropriate algorithms to detect rearrangements. Bioinformatics
tools for copy number alterations (CNAs) calling such as ASCAT-2, CNVkit or ANACONDA will be
used for the assessment of focal gene amplification or deletion events. Read depth-based
analysis will also be taken into consideration for assessment of gene-level CNAs. Appropriate
variant annotators will be used to annotate the identified alterations to each gene. Germline
variant databases such as ClinVar will be used for the classification of variants according
to the ACMG guidelines.
